[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqvSDFgqcA3ihbGZ1FEcoHzDLWQKfz_xaX9RXKb-0w-g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"Fundacion Dexeus",[4],35,false,5,1,8649,3,23,[14,17,19,22,24,26,28,30],{"name":15,"count":16},"Infertility",18,{"name":18,"count":11},"Oocyte Donation",{"name":20,"count":21},"Embryo Transfer",2,{"name":23,"count":21},"Polycystic Ovary Syndrome",{"name":25,"count":21},"Infertility, Female",{"name":27,"count":21},"Progesterone",{"name":29,"count":21},"Preimplantation Genetic Screening",{"name":31,"count":21},"Fertility Disorders",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","2026-01-15","Subcutaneous Triptorelin",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","2027-02","Semaglutide",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,75,97,115,140,165,192,217,256,286,304,329,347,375,393,411],{"intervention":42,"totalTrials":9,"cells":52},{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":62,"NA":73},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":55},[],{"trials":63,"activeCount":9,"soonestReadout":41},[64],{"nctId":39,"briefTitle":40,"status":65,"phases":66,"primaryCompletion":41,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"RECRUITING",[48],"2027-05","2026-01-19",62,[15,71],"Obesity",[42],{"trials":74,"activeCount":55},[],{"intervention":37,"totalTrials":9,"cells":76},{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":95},{"trials":78,"activeCount":55},[],{"trials":80,"activeCount":55},[],{"trials":82,"activeCount":55},[],{"trials":84,"activeCount":55},[],{"trials":86,"activeCount":9,"soonestReadout":36},[87],{"nctId":34,"briefTitle":35,"status":88,"phases":89,"primaryCompletion":36,"completion":36,"start":90,"enrollment":91,"conditions":92,"interventions":93},"NOT_YET_RECRUITING",[48],"2025-03-15",134,[31],[37,94],"Intranasal nafarelin",{"trials":96,"activeCount":55},[],{"intervention":94,"totalTrials":9,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":113},{"trials":100,"activeCount":55},[],{"trials":102,"activeCount":55},[],{"trials":104,"activeCount":55},[],{"trials":106,"activeCount":55},[],{"trials":108,"activeCount":9,"soonestReadout":36},[109],{"nctId":34,"briefTitle":35,"status":88,"phases":110,"primaryCompletion":36,"completion":36,"start":90,"enrollment":91,"conditions":111,"interventions":112},[48],[31],[37,94],{"trials":114,"activeCount":55},[],{"intervention":116,"totalTrials":9,"cells":117},"Corifollitropin alfa",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":138},{"trials":119,"activeCount":55},[],{"trials":121,"activeCount":55},[],{"trials":123,"activeCount":55},[],{"trials":125,"activeCount":55},[],{"trials":127,"activeCount":55},[128],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT02490150","Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill","COMPLETED",[48],"2016-06","2015-02",70,[18],[116],{"trials":139,"activeCount":55},[],{"intervention":141,"totalTrials":9,"cells":142},"FSH-CTP + DESOGESTREL",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":163},{"trials":144,"activeCount":55},[],{"trials":146,"activeCount":55},[],{"trials":148,"activeCount":55},[],{"trials":150,"activeCount":55},[],{"trials":152,"activeCount":55},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":159,"start":160,"enrollment":55,"conditions":161,"interventions":162},"NCT02757287","Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors","WITHDRAWN",[48],"2017-11-01","2018-12-01","2016-05",[15],[141],{"trials":164,"activeCount":55},[],{"intervention":166,"totalTrials":9,"cells":167},"Testosterone gel",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":188,"NA":190},{"trials":169,"activeCount":55},[],{"trials":171,"activeCount":55},[],{"trials":173,"activeCount":55},[],{"trials":175,"activeCount":55},[176],{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT02418572","Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial","TERMINATED",[47],"2023-12","2024-02","2015-04",290,[15,186],"Poor Ovarian Response",[166],{"trials":189,"activeCount":55},[],{"trials":191,"activeCount":55},[],{"intervention":193,"totalTrials":9,"cells":194},"Somatropin",{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":196,"activeCount":55},[],{"trials":198,"activeCount":55},[],{"trials":200,"activeCount":55},[201],{"nctId":202,"briefTitle":203,"status":179,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT01298960","Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients",[46],"2013-06","2011-02",52,[209],"Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer",[193],{"trials":212,"activeCount":55},[],{"trials":214,"activeCount":55},[],{"trials":216,"activeCount":55},[],{"intervention":218,"totalTrials":21,"cells":219},"Micronized progesterone",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":230},{"trials":221,"activeCount":55},[],{"trials":223,"activeCount":55},[],{"trials":225,"activeCount":55},[],{"trials":227,"activeCount":55},[],{"trials":229,"activeCount":55},[],{"trials":231,"activeCount":55},[232,245],{"nctId":233,"briefTitle":234,"status":131,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":243},"NCT04108039","Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.",[49],"2022-01-15","2022-05-15","2019-09-25",44,[15,241,242],"IVF","Preimplantation Diagnosis",[244,218],"GnRh antagonist",{"nctId":246,"briefTitle":247,"status":131,"phases":248,"primaryCompletion":134,"completion":134,"start":249,"enrollment":250,"conditions":251,"interventions":254},"NCT03088046","Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome",[49],"2014-02",15,[252,23,253],"Anovulation","Hyperandrogenism",[255],"Micronized Progesterone",{"intervention":257,"totalTrials":9,"cells":258},"Low Progesterone",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":260,"activeCount":55},[],{"trials":262,"activeCount":55},[],{"trials":264,"activeCount":55},[],{"trials":266,"activeCount":55},[],{"trials":268,"activeCount":55},[],{"trials":270,"activeCount":55},[271],{"nctId":272,"briefTitle":273,"status":131,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":284},"NCT03740568","Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.",[49],"2020-02-28","2018-11-15",598,[15,27,279,280,281,282,283],"Frozen Embryo Transfer","Euploid Embryo Transfer","Pregnancy Outcome","Artificial Cycle","Ongoing Pregnancy",[257,285],"Normal Progesterone",{"intervention":285,"totalTrials":9,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":289,"activeCount":55},[],{"trials":291,"activeCount":55},[],{"trials":293,"activeCount":55},[],{"trials":295,"activeCount":55},[],{"trials":297,"activeCount":55},[],{"trials":299,"activeCount":55},[300],{"nctId":272,"briefTitle":273,"status":131,"phases":301,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":302,"interventions":303},[49],[15,27,279,280,281,282,283],[257,285],{"intervention":305,"totalTrials":9,"cells":306},"Follicular phase corifollitropin alfa",{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":317},{"trials":308,"activeCount":55},[],{"trials":310,"activeCount":55},[],{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[],{"trials":316,"activeCount":55},[],{"trials":318,"activeCount":55},[319],{"nctId":320,"briefTitle":321,"status":131,"phases":322,"primaryCompletion":323,"completion":324,"start":325,"enrollment":239,"conditions":326,"interventions":327},"NCT03555942","Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa",[49],"2021-11-30","2021-12-01","2018-05-08",[15],[305,328],"Luteal phase corifollitropin alfa",{"intervention":328,"totalTrials":9,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":332,"activeCount":55},[],{"trials":334,"activeCount":55},[],{"trials":336,"activeCount":55},[],{"trials":338,"activeCount":55},[],{"trials":340,"activeCount":55},[],{"trials":342,"activeCount":55},[343],{"nctId":320,"briefTitle":321,"status":131,"phases":344,"primaryCompletion":323,"completion":324,"start":325,"enrollment":239,"conditions":345,"interventions":346},[49],[15],[305,328],{"intervention":348,"totalTrials":9,"cells":349},"gonadotropins plus GnRH antagonists",{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":351,"activeCount":55},[],{"trials":353,"activeCount":55},[],{"trials":355,"activeCount":55},[],{"trials":357,"activeCount":55},[],{"trials":359,"activeCount":55},[],{"trials":361,"activeCount":55},[362],{"nctId":363,"briefTitle":364,"status":131,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":250,"conditions":368,"interventions":373},"NCT01645241","Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation",[49],"2013-12","2012-07",[369,370,371,372,18],"INFERTILITY","Fertility Preservation","Ovulation Induction","Vitrification",[348,374],"ganirelix",{"intervention":374,"totalTrials":9,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":378,"activeCount":55},[],{"trials":380,"activeCount":55},[],{"trials":382,"activeCount":55},[],{"trials":384,"activeCount":55},[],{"trials":386,"activeCount":55},[],{"trials":388,"activeCount":55},[389],{"nctId":363,"briefTitle":364,"status":131,"phases":390,"primaryCompletion":366,"completion":366,"start":367,"enrollment":250,"conditions":391,"interventions":392},[49],[369,370,371,372,18],[348,374],{"intervention":244,"totalTrials":9,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":396,"activeCount":55},[],{"trials":398,"activeCount":55},[],{"trials":400,"activeCount":55},[],{"trials":402,"activeCount":55},[],{"trials":404,"activeCount":55},[],{"trials":406,"activeCount":55},[407],{"nctId":233,"briefTitle":234,"status":131,"phases":408,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":409,"interventions":410},[49],[15,241,242],[244,218],{"intervention":412,"totalTrials":9,"cells":413},"Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa",{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":415,"activeCount":55},[],{"trials":417,"activeCount":55},[],{"trials":419,"activeCount":55},[],{"trials":421,"activeCount":55},[],{"trials":423,"activeCount":55},[],{"trials":425,"activeCount":55},[426],{"nctId":427,"briefTitle":428,"status":131,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT03354494","Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors",[],"2017-06","2017-09","2016-01",40,[435],"Controlled Ovaria Stimulation",[412]]